The FDA is expected to decide whether or not to approve Amgen Inc.’s (AMGN) Otezla in the additional indication of treating adults with mild-to-moderate plaque psoriasis on December 19.Otezla is already approved in the U.S. for the treatment of adult patients with active psoriatic arthritis, moderate to severe plaque psoriasis, and oral ulcers associated with Behçet’s Disease.The drug generated total sales of $609 million in the third quarter of 2021 compared to $538 million in the year-ago period.AMGN closed Friday’s trading at $201.09, down 1.41%.